Table 3.

Treatment-related adverse events

	Anti-PD-1 plus chemotherapy (n = 38)		Anti-PD-1 monotherapy (n = 20)		Chemotherapy (n = 19)
Adverse event	Grade 1–4	Grade 3–4	Grade 1–4	Grade 3–4	Grade 1–4	Grade 3–4
Any term	29 (76.3%)	13 (34.2%)	4 (20.0%)	1 (5.0%)	14 (73.7%)	7 (36.8%)
Nausea	17 (44.7%)	0	1 (5.0%)	0	7 (36.8%)	0
Diarrhea	0	0	1 (5.0%)	0	0	0
Fatigue	0	0	0	0	0	0
Anemia	4 (10.5%)	0	0	0	1 (5.3%)	0
Alopecia	1 (2.6%)	1 (2.6%)	0	0	1 (5.3%)	0
Skin rash	2 (5.3%)	0	0	0	1 (5.3%)	0
Vomiting	1 (2.6%)	0	0	0	4 (21.1%)	0
Hepatitis	1 (2.6%)	0	0	0	0	0
Increased aspartate aminotransferase (AST)	2 (5.3%)	0	3 (15.0%)	0	0	0
Thrombocytopenia	15 (39.5%)	11 (28.9%)	1 (5.0%)	1 (5.0%)	2 (10.5%)	2 (10.5%)
Leukopenia	15 (39.5%)	3 (7.9%)	0	0	8 (42.1%)	5 (26.3%)
Intestinal obstruction	0	0	0	0	1 (5.3%)	0
Increased alanine aminotransferase (ALT)	0	0	0	0	3 (15.8%)	0
Peripheral neuritis	0	0	0	0	2 (10.5%)	0
Hypodynamia	0	0	3 (15%)	0	0	0
Hypothyreosis	0	0	1 (5.0%)	0	0	0
Myodynia	0	0	1 (5.0%)	0	0	0